Skip to main content

Advertisement

Table 7 TCP-5 profiles, molecules with transmission-blocking activity

From: New developments in anti-malarial target candidate and product profiles

TCP-5: general considerations Minimum essential Ideal
Dosing regimen: adult/pediatric dose Oral, single dose (predicted) <1000 mg/<250 mg; oral, three doses <400 mg/<100 mg for areas of multidrug resistance Oral, single dose (predicted); <100 mg/25 mg
Efficacy Prevents transmission prevalence to mosquito >90% in appropriate clinical protocol Prevents transmission prevalence to mosquito >90% at 15 days post oral dose
Safety and tolerability Therapeutic ratio >tenfold between therapeutic exposure and NOAEL in preclinical studies and easily monitorable adverse event or biomarker for human studies Therapeutic ratio >50-fold between therapeutic exposure and NOAEL in preclinical studies and easily monitorable adverse event or biomarker for human studies
G6PD deficiency status New candidate drug shows no enhanced hemolytic risk in preclinical model, and no concerns for severe G6PD deficiency  
Drug-drug interactions No unmanageable risks No interactions with other anti-malarial, anti-retroviral or TB medicines
Formulation Simple and inexpensive to produce, not requiring proprietary methodology or kits; can readily be produced in endemic countries Formulation without complex excipients possible; simple and inexpensive to produce, not requiring proprietary methodology or kits; can readily be produced in endemic countries
Cost of single treatment Similar to current medications for asexual stages: $0.50 for adults Similar or better than current transmission-blocking low dose primaquine <$0.05 for adults, $0.01 for infants for transmission-blocking
Projected stability of final product under Zone IVb conditions (30 °C, 75% humidity) ≥36 months ≥5 years